Table 2.
Characteristics of the randomized control studies comparing RTCH and HT.
| Study and year | N | EBRT TD/fx Gy | BT (Gy) | FIGO | Follow up (months) | CT | CR RT | CR investigated arm | LC RTCT | LC investigated arm | OS RTCT | OS investigated arm |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zolciak-Siwinska 201344 | 205 | 45–50/1.8–2.0 +10 boost LN+ |
30/7.5 HDR | II-III | 45 | CDDP 40 mg weekly | – | – | 87% | RTCT+BT HT* 90% (NS) | 70% 3yr DFS | RTCT+BT HT* 62% (NS) 3yr DFS |
| Lutgens 2016 RADCHOC 42 | 84 | 50/2.0 | 21/7.0 HDR 29 MDR 32 LDR |
IB2-IVA | 85 | CDDP 40 mg weekly | – | – | 78% | RT+HT 80% (NS) | 69% | RT+HT 69%(NS) |
| Harima 201628 | 101 | 20–31.2/1.8–2.0 WPRT + 10–22 (Central) | 20–30/5–6 HDR | IB-IVA | 47–63 | CDDP 30–40 mg weekly | 77% | RTCT + HT 88%(SS) | 60.6% | RTCT + HT 70.8% (NS) | 71% | RTCT+HT 80% (NS) |
BT: brachytherapy; CR: complete response; CT: chemotherapy; DFS: disease free survival; EBRT: external beam radiotherapy; FIGO: International Federation of Gynacology and Obstetrics; fx: fraction dose; HT: hyperthermia; LC: local control; N: number; NS: not significant; OS: overall survival; RT: radiotherapy; SS: statistical significant; TD: total dose; yr: years.
*
Interstitial HT.